Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.02 - $3.23 $99,685 - $315,671
97,731 Added 118.34%
180,318 $227,000
Q4 2023

Feb 14, 2024

BUY
$1.72 - $3.18 $18,490 - $34,185
10,750 Added 14.96%
82,587 $225,000
Q3 2023

Nov 14, 2023

BUY
$2.13 - $5.55 $113,313 - $295,254
53,199 Added 285.43%
71,837 $163,000
Q2 2023

Aug 14, 2023

SELL
$3.6 - $5.25 $22,737 - $33,159
-6,316 Reduced 25.31%
18,638 $81,000
Q1 2023

May 15, 2023

BUY
$4.3 - $8.27 $107,302 - $206,369
24,954 New
24,954 $111,000
Q2 2022

Aug 15, 2022

SELL
$2.6 - $6.14 $52,423 - $123,800
-20,163 Reduced 39.98%
30,266 $95,000
Q1 2022

May 16, 2022

BUY
$5.08 - $9.81 $80,518 - $155,488
15,850 Added 45.84%
50,429 $287,000
Q4 2021

Feb 14, 2022

BUY
$8.55 - $111.89 $269,102 - $3.52 Million
31,474 Added 1013.66%
34,579 $339,000
Q3 2021

Nov 15, 2021

BUY
$76.53 - $110.43 $237,625 - $342,885
3,105 New
3,105 $329,000
Q2 2021

Aug 16, 2021

SELL
$85.37 - $114.1 $717,790 - $959,352
-8,408 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$109.73 - $153.66 $714,013 - $999,865
6,507 Added 342.29%
8,408 $965,000
Q4 2020

Feb 16, 2021

SELL
$79.58 - $152.45 $722,745 - $1.38 Million
-9,082 Reduced 82.69%
1,901 $266,000
Q3 2020

Nov 16, 2020

SELL
$66.43 - $90.99 $32,152 - $44,039
-484 Reduced 4.22%
10,983 $895,000
Q2 2020

Aug 17, 2020

SELL
$44.04 - $80.69 $66,500 - $121,841
-1,510 Reduced 11.64%
11,467 $824,000
Q1 2020

May 15, 2020

SELL
$44.49 - $93.39 $52,587 - $110,386
-1,182 Reduced 8.35%
12,977 $577,000
Q4 2019

Feb 14, 2020

BUY
$66.49 - $137.73 $941,431 - $1.95 Million
14,159 New
14,159 $1.35 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $98.3M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.